PCM
JSPR icon

Prelude Capital Management’s Jasper Therapeutics JSPR Stock Holding History

Prelude Capital Management’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-5,450
Closed -$98.6K – 1242
2023
Q1 		$98.6K Buy
+5,450
New +$101K 0.01% 951
2021
Q3 		– Sell
-10,100
Closed -$1M – 1878
2021
Q2 		$1M Hold
10,100
– – 0.03% 612
2021
Q1 		$1M Buy
+10,100
New +$1.03M 0.03% 603

Other funds holding JSPR

VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Prelude Capital Management's JSPR Position: Q2 2023 in Review

Prelude Capital Management sold out of Jasper Therapeutics (JSPR) in Q2 2023, closing a stake of 5,450 shares — an estimated $98.6K sold.

Prelude Capital Management first reported a position in JSPR in Q1 2021 and held it in 3 quarters. The position peaked at $1M in Q2 2021. 46 funds tracked by Wall St. Rank hold JSPR as of Q2 2023.

  • Prelude Capital Management reported no remaining Jasper Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Prelude Capital Management sold 5,450 Jasper Therapeutics shares in Q2 2023, an estimated $98.6K.
  • Prelude Capital Management first reported a position in Jasper Therapeutics in Q1 2021 and held it in 3 quarters.
  • Prelude Capital Management's Jasper Therapeutics position peaked at $1M in Q2 2021.
  • 46 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q2 2023.

Based on Prelude Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.